Showing 1431-1440 of 2656 results for "".
- Sources Say US Study of AstraZeneca’s COVID-19 Vaccine May Restart This Weekhttps://modernod.com/news/sources-say-us-study-of-astrazenecas-covid-19-vaccine-may-restart-this-week/2478439/According to a report Tuesday citing four sources, the US trial of AstraZeneca’s COVID-19 vaccine AZD1222 is expected to resume as early as this week after the FDA completed its review of a serious adverse event that had prompted a hold on global testing of the candidate last month. The pha
- Study of Lilly’s COVID-19 Antibody LY-CoV555 Paused Over Potential Safety Issuehttps://modernod.com/news/study-of-lillys-covid-19-antibody-ly-cov555-paused-over-potential-safety-issue/2478416/A phase 3 trial of Eli Lilly’s investigational monoclonal antibody LY-CoV555 for the treatment of COVID-19 has been temporarily suspended out of an “abundance of caution” because of a “potential safety concern,” according to emails that government officials sent on T
- EMA Starts Rolling Review of AstraZeneca’s COVID-19 Vaccine Candidate AZD1222https://modernod.com/news/ema-starts-rolling-review-of-astrazenecas-covid-19-vaccine-candidate-azd1222/2478359/The European Medicines Agency said Thursday that its Committee for Medicinal Products for Human Use (CHMP) has initiated a rolling review of AstraZeneca and the University of Oxford’s COVID-19 vaccine candidate AZD1222. The agency explained that the start of the rolling review, the first fo
- J&J’s COVID-19 Vaccine “Highly Immunogenic” in Early-Stage Testinghttps://modernod.com/news/jjs-covid-19-vaccine-highly-immunogenic-in-early-stage-testing/2478332/Interim phase 1/2a study results for Johnson & Johnson’s experimental COVID-19 vaccine JNJ-78436735 have been published online on the preprint server medRxiv, with researchers saying that a single dose was “well tolerated and highly immunogenic,” and that the findings warran
- Bascom Palmer Eye Institute Ranked Nation’s No. 1 in Ophthalmology for 19th Timehttps://modernod.com/news/bascom-palmer-eye-institute-ranked-nations-no-1-in-ophthalmology-for-19th-time/2478089/Bascom Palmer Eye Institute of the University of Miami Health System has been ranked again as the nation’s best in ophthalmology by U.S News & World Report. This year marks the 19th time, and the 17th consecutive year, that
- Moderna’s COVID-19 Vaccine Candidate Induces “Robust” Response In All Patients Testedhttps://modernod.com/news/modernas-covid-19-vaccine-candidate-induces-robust-response-in-all-patients-tested/2478023/The NEJM published an interim analysis Tuesday of an ongoing phase 1 trial showing that Moderna’s experimental COVID-19 vaccine mRNA-1273 induced anti–SARS-CoV-2 immune responses in all participants, with the authors saying there were “no trial-limiting safety concerns.”
- EyePoint Pharmaceuticals Names Jay S. Duker, MD, Chief Strategic Scientific Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-names-jay-s-duker-md-chief-strategic-scientific-officer/2478005/EyePoint Pharmaceuticals announced the appointment of Jay S. Duker, MD, as Chief Strategic Scientific Officer. In this newly created role, Dr. Duker will lead the strategic advancement of our research and development efforts, beginning with our lead development candidate EYP-1901 for wet age-rela
- Sanofi, Regeneron’s Kevzara Fails Late-Stage Study in COVID-19https://modernod.com/news/sanofi-regenerons-kevzara-fails-late-stage-study-in-covid-19/2477966/Sanofi and Regeneron Pharmaceuticals announced Thursday that a phase 3 trial of their rheumatoid arthritis drug Kevzara (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints when the IL-6 receptor antibody was added to best s
- Lilly Begins World’s First Human Study of Antibody to Treat COVID-19https://modernod.com/news/lilly-begins-worlds-first-human-study-of-antibody-to-treat-covid-19/2477853/Eli Lilly said that the first patients have been dosed in a phase 1 trial investigating the experimental antibody LY-CoV555 for the treatment of COVID-19. The company, which is developing the drug with partner AbCellera, noted that the move marks the world’s first study of a potential antib
- Chinese Official Claims Fujifilm’s Avigan “Clearly Effective” in Treating COVID-19https://modernod.com/news/chinese-official-claims-fujifilms-avigan-clearly-effective-in-treating-covid-19/2477411/Results of clinical studies conducted in China suggest that Fujifilm’s Avigan (favipiravir) may be effective at treating patients with COVID-19. Zhang Xinmin, director of the China National Center for Biotechnology Development under the Ministry of Science and Technology, remarked “it